+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia

Core Evidence 1(1): 1-12

Current therapy options for chronic myeloid leukemia (CML) include conventional chemotherapy, allogeneic stem cell transplant, interferon-alfa, and imatinib mesylate, which has recently achieved gold standard status. Although the majority of patients initially respond well to treatment with imatinib, wider clinical experience with this drug has resulted in the development of imatinib resistance being increasingly documented. There is therefore an unmet medical need for novel therapies to override imatinib resistance in CML. This review summarizes the emerging evidence for the potential use of dasatinib in the treatment of imatinib-resistant CML. Dasatinib is a novel small molecule that has shown potent antileukemic activity in imatinib-resistant cell lines, malignant marrow cells isolated from patients with imatinib-resistant CML, and in mouse xenograft models of imatinib-resistant CML. Preliminary data from an initial phase I dose escalation trial have been encouraging, indicating that dasatinib is generally well tolerated and produces hematologic and cytogenetic responses in patients with imatinib-resistant CML in all phases of the disease. The maximum tolerated dose (MTD) has not yet been reached, and dose escalation continues to determine the dose range that yields optimal results. Although dasatinib is still in the early stages of development, the potential impact of this molecule on the treatment of CML could be revolutionary, not only providing a much needed treatment option for patients with imatinib-resistant CML, but also, combined with imatinib, could possibly prove useful in delaying the onset of resistance to treatment. Furthermore, combined with other agents active in CML, dasatinib could have potential utility in purging residual leukemic cells in patients whose disease is controlled by imatinib.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 052448406

Download citation: RISBibTeXText

PMID: 22496672

Related references

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. Clinical Advances in Hematology and Oncology 9(10): 734-745, 2011

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. Clinical Lymphoma Myeloma and Leukemia 18(5): 353-360.E1, 2018

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Clinical Therapeutics 34(2): 272-281, 2012

The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leukemia and Lymphoma 52(5): 754-763, 2011

Dasatinib in the Treatment of Chronic Myeloid Leukemia. Current Signal Transduction Therapy 6(1): 99-105, 2011

Dasatinib for the treatment of chronic myeloid leukemia. Expert Review of Hematology 4(3): 253-260, 2011

Dasatinib in the first-line treatment of chronic myeloid leukemia. Community Oncology 9(11), 2012

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biologics 3: 205-214, 2009

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Annals of PharmacoTherapy 43(5): 920-927, 2009

Dasatinib and nilotinib in first-line treatment of chronic myeloid leukemia. Community Oncology 7(11): 491-493, 2010

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia. Journal of Blood Medicine 1: 221-225, 2010

Dasatinib dose management for the treatment of chronic myeloid leukemia. Cancer 124(8): 1660-1672, 2018

Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clinical Medicine Insights. Oncology 4: 155-162, 2010

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114(24): 4944-4953, 2009

Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase. Zhonghua Xue Ye Xue Za Zhi 40(2): 98, 2019